Equities analysts predict that vTv Therapeutics Inc (NASDAQ:VTVT) will announce earnings of ($0.14) per share for the current quarter, Zacks reports. Two analysts have issued estimates for vTv Therapeutics’ earnings. vTv Therapeutics posted earnings of ($0.10) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 40%. The firm is expected to report its next quarterly earnings results on Wednesday, February 26th.
According to Zacks, analysts expect that vTv Therapeutics will report full-year earnings of ($0.44) per share for the current financial year. For the next year, analysts anticipate that the business will post earnings of ($0.55) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow vTv Therapeutics.
vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $1.69 million.
Shares of NASDAQ VTVT traded up $0.02 during mid-day trading on Friday, reaching $1.53. 248,856 shares of the company’s stock traded hands, compared to its average volume of 98,159. The business has a 50-day simple moving average of $1.50 and a 200 day simple moving average of $1.45. vTv Therapeutics has a 1-year low of $1.00 and a 1-year high of $3.50.
In other news, major shareholder Ronald O. Perelman acquired 606,061 shares of vTv Therapeutics stock in a transaction on Wednesday, September 18th. The stock was acquired at an average cost of $1.65 per share, for a total transaction of $1,000,000.65. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Ronald O. Perelman acquired 1,369,863 shares of vTv Therapeutics stock in a transaction on Friday, September 27th. The shares were purchased at an average price of $1.46 per share, with a total value of $1,999,999.98. The disclosure for this purchase can be found here. Insiders have acquired a total of 6,085,513 shares of company stock valued at $9,000,001 in the last three months. 1.70% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in shares of vTv Therapeutics by 25.7% in the second quarter. BlackRock Inc. now owns 65,031 shares of the biotechnology company’s stock worth $93,000 after buying an additional 13,305 shares during the last quarter. Wedbush Securities Inc. purchased a new position in vTv Therapeutics during the third quarter valued at approximately $39,000. Finally, Virtu Financial LLC lifted its holdings in vTv Therapeutics by 162.4% during the third quarter. Virtu Financial LLC now owns 76,541 shares of the biotechnology company’s stock valued at $119,000 after purchasing an additional 47,369 shares in the last quarter. 5.66% of the stock is currently owned by hedge funds and other institutional investors.
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Further Reading: Bond
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.